Zobrazeno 1 - 10
of 146
pro vyhledávání: '"D, van Tol"'
Autor:
Astrid G. S. van Halteren, Jessica S. Suwandi, Sander Tuit, Jelske Borst, Sandra Laban, Roula Tsonaka, Ada Struijk, Anna-Sophia Wiekmeijer, Melissa van Pel, Bart O. Roep, Jaap Jan Zwaginga, Arjan C. Lankester, Koen Schepers, Maarten J. D. van Tol, Willem E. Fibbe
Publikováno v:
Blood. 141(11):1277-1292
Acute graft-versus-host disease (aGVHD) is an immune cell‒driven, potentially lethal complication of allogeneic hematopoietic stem cell transplantation affecting diverse organs, including the skin, liver, and gastrointestinal (GI) tract. We applied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4806f577f9ab625e12cf2e9aa317027
https://doi.org/10.1182/blood.2022015734
https://doi.org/10.1182/blood.2022015734
Autor:
Federica R. Achini-Gutzwiller, Cornelia M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Arjan C. Lankester, Robbert G. M. Bredius, Maarten J. D. van Tol, Dirk Jan A. R. Moes, Marco W. Schilham
Publikováno v:
Therapeutic Drug Monitoring. 45:79-86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91b4550e643339ae76e1700351ec5a1d
https://doi.org/10.1097/ftd.0000000000001037
https://doi.org/10.1097/ftd.0000000000001037
Autor:
Lisa V. E. Oostenbrink, Cornelia M. Jol-van der Zijde, Katrine Kielsen, Anja M. Jansen-Hoogendijk, Marianne Ifversen, Klaus G. Müller, Arjan C. Lankester, Astrid G. S. van Halteren, Robbert G. M. Bredius, Marco W. Schilham, Maarten J. D. van Tol
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Anti-thymocyte globulin (ATG) is a lymphocyte depleting agent applied in hematopoietic stem cell transplantation (HSCT) to prevent rejection and Graft-vs.-Host Disease (GvHD). In this study, we compared two rabbit ATG products, ATG-Genzyme (ATG-GENZ)
Externí odkaz:
https://doaj.org/article/8044e135e7df45b3a36d392be8be61d7
Autor:
Noortje de Haan, Maarten J. D. van Tol, Gertjan J. Driessen, Manfred Wuhrer, Arjan C. Lankester
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Immunoglobulin G (IgG) fragment crystallizable (Fc) N-glycosylation has a large influence on the affinity of the antibody for binding to Fcγ-receptors (FcγRs) and C1q protein, thereby influencing immune effector functions. IgG Fc glycosylation is k
Externí odkaz:
https://doaj.org/article/d16c88fc10b941f896c2ad3bad1ec2b9
Autor:
Federica R, Achini-Gutzwiller, Cornelia M, Jol-van der Zijde, Anja M, Jansen-Hoogendijk, Arjan C, Lankester, Robbert G M, Bredius, Maarten J D, van Tol, Dirk Jan A R, Moes, Marco W, Schilham
Publikováno v:
Therapeutic drug monitoring.
Alemtuzumab is a humanized monoclonal antibody that targets the CD52 glycoprotein expressed on most lymphocytes, subsequently inducing complement- and antibody-mediated cytotoxicity. Owing to its ability to induce profound immune depletion, alemtuzum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cb78139e7f32137c9e0e172e30ab144b
https://pubmed.ncbi.nlm.nih.gov/36150715
https://pubmed.ncbi.nlm.nih.gov/36150715
Autor:
Anja M. Jansen-Hoogendijk, Astrid G. S. van Halteren, Robbert G. M. Bredius, Maarten J. D. van Tol, Alexander B. Mohseny, Lisa V E Oostenbrink, Emma S. Pool, Arjan C. Lankester, Cornelia M. Jol-van der Zijde, Frans J. Smiers, Carly Vervat, Marco W. Schilham
Publikováno v:
Bone Marrow Transplantation. SPRINGERNATURE
Bone Marrow Transplantation
Bone Marrow Transplantation
The use of HLA-mismatched (un)related donors is historically associated with a higher incidence of transplant-related complications and mortality. However, the use of such donors may overcome the limited availability of HLA-matched donors for patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38207222d3da57c4be2cd535e0994a48
https://doi.org/10.1038/s41409-021-01302-0
https://doi.org/10.1038/s41409-021-01302-0
Autor:
Maarten J. D. van Tol, Anja M. Jansen-Hoogendijk, Cornelia M. Jol-van der Zijde, Robbert G. M. Bredius, Astrid G. S. van Halteren, Emma S. Pool, Dirk Jan A.R. Moes, Alex B. Mohseny, Lisa V E Oostenbrink, Marco W. Schilham, Arjan C. Lankester, Frans J. Smiers
Publikováno v:
Hematology/Oncology and Stem Cell Therapy, Vol 13, Iss 2, Pp 61-65 (2020)
Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease. Although weight-based dosing of ATG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2594476ae6df9a17f1469d07ac85ad4c
http://www.sciencedirect.com/science/article/pii/S1658387620300182
http://www.sciencedirect.com/science/article/pii/S1658387620300182
Autor:
Peter E. Thijssen, Yuya Ito, Giacomo Grillo, Jun Wang, Guillaume Velasco, Hirohisa Nitta, Motoko Unoki, Minako Yoshihara, Mikita Suyama, Yu Sun, Richard J. L. F. Lemmers, Jessica C. de Greef, Andrew Gennery, Paolo Picco, Barbara Kloeckener-Gruissem, Tayfun Güngör, Ismail Reisli, Capucine Picard, Kamila Kebaili, Bertrand Roquelaure, Tsuyako Iwai, Ikuko Kondo, Takeo Kubota, Monique M. van Ostaijen-Ten Dam, Maarten J. D. van Tol, Corry Weemaes, Claire Francastel, Silvère M. van der Maarel, Hiroyuki Sasaki
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-2 (2016)
Nature Communications 6: Article number: 7870 (2015); Published: 28 July 2015; Updated: 22 June 2016 In Fig. 1b of this Article, the sex of patient 2.1 in family A is incorrect, and should be depicted as male. The correct version of this figure appea
Externí odkaz:
https://doaj.org/article/39037390f270467296e8d2c54de0aed6
Autor:
Astrid G. S. van Halteren, Arjan C. Lankester, Marianne Ifversen, Lisa V E Oostenbrink, Robbert G. M. Bredius, Cornelia M. Jol-van der Zijde, Erik G J von Asmuth, Marco W. Schilham, Maarten J. D. van Tol, Anja M. Jansen-Hoogendijk, Klaus Müller, Katrine Kielsen, Carsten Heilmann, Monique M. van Ostaijen-ten Dam
Publikováno v:
Journal of Immunology, 206(12), 2828-2838. AMER ASSOC IMMUNOLOGISTS
Differentially and functionally distinct T cell subsets are involved in the development of complications after allogeneic hematopoietic stem cell transplantation (HSCT), but little is known about factors regulating their recovery after HSCT. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17915f30c6f1c1c4c11e850ad35b8d1
https://hdl.handle.net/1887/3264386
https://hdl.handle.net/1887/3264386
Autor:
Peter E. Thijssen, Qiang Pan-Hammarström, Mélanie Rogier, Girish M. Shah, Gwendolynn Grootaers, Mirjam van der Burg, Anton J.L. de Groot, Angela Helfricht, Rianca Jak, Alfred C.O. Vertegaal, Monique M. van Ostaijen-ten Dam, Jun Wang, Vincent Heyer, Magdalena B. Rother, Likun Du, Hanna IJspeert, Jacques Moritz, Maarten J. D. van Tol, Haico van Attikum, Bernardo Reina-San-Martin, Pooja Rao, Sanami Takada, Rashmi G. Shah, Martijn S. Luijsterburg, Silvère M. van der Maarel, Chantal Stoepker
Publikováno v:
Journal of Experimental Medicine, 217(11). ROCKEFELLER UNIV PRESS
The Journal of experimental medicine, 217(11)
The Journal of Experimental Medicine
The Journal of experimental medicine, 217(11)
The Journal of Experimental Medicine
Mutations in ZBTB24 cause immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome. Helfricht et al. demonstrate that the loss of ZBTB24 impairs nonhomologous end-joining and class-switch recombination, proving a molecular basis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0193041240ab8d67e08c4936d5e79ad
https://hdl.handle.net/1887/3182619
https://hdl.handle.net/1887/3182619